• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Regencell Bioscience Holdings Limited

    6/2/25 6:28:09 AM ET
    $RGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RGC alert in real time by email
    6-K 1 ea0244186-6k_regencell.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

     

    Commission File Number: 001-40617

     

     

    Regencell Bioscience Holdings Limited

    (Registrant’s Name) 

     

     

    9/F Chinachem Leighton Plaza

    29 Leighton Road

    Causeway Bay, Hong Kong

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒            Form 40-F ☐

     

     

     

     

     

     

    Forward Stock Split

     

    The board of directors of Regencell Bioscience Holdings Limited (the “Company”) approved a 38-for-one forward stock split to be paid in the form of a stock bonus. Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025. Subject to the final approval by the Nasdaq Capital Market, trading is expected to begin on a post-stock split adjusted basis at market open on June 16, 2025.

     

    Following the split, the Company’s outstanding shares will be increased at the ratio of the forward stock split. The Company’s authorized share capital and the share par value will remain unchanged.

     

    There will be no change to the Company’s name, CUSIP or its current trading symbol in connection with the forward stock split.

     

    No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company’s transfer agent.

     

    Exhibit No.   Description
    99.1   Press Release, dated June 2, 2025

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: June 2, 2025

     

      Regencell Bioscience Holdings Limited
         
      By: /s/ Yat-Gai Au
      Name: Yat-Gai Au
      Title: Chief Executive Officer and
    Chairman of the Board of Directors

     

    2

     

    Get the next $RGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RGC
    SEC Filings

    See more
    • SEC Form 6-K filed by Regencell Bioscience Holdings Limited

      6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

      6/17/25 6:08:27 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Regencell Bioscience Holdings Limited

      6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

      6/2/25 6:28:09 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Regencell Bioscience Holdings Limited

      6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

      1/15/25 6:02:56 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care